Current and Emerging Treatment Options for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Carcinoma)

Released On
June 15, 2020

Expires On
June 15, 2021

Media Type

Completion Time
150 minutes

Hematology-Oncology, Nephrology, Urology


Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Amedco LLC and CancerNet LLC.


This activity is supported in part by an independent education grant from Bristol-Myers Squibb, Merck Sharp & Dohme Corp. and Eisai, Inc.

Credit Available

  • Physicians, Physicians Assistants, Nurse Practitioners — maximum of 2.5 AMA PRA Category 1 Credit(s)
  • Nurses — Maximum of 2.5 CNE Contact Hours
  • Pharmacists — Maximum of 2.5 contact hours (0.25 CEUs) knowledge-based credits

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of medical oncologists, urologists, radiation oncologists, nurse practitioners, physician assistants, nurses, pharmacists on the latest advances in the diagnosis, and treatment of genitourinary cancers (prostate cancer, renal cell carcinoma and urothelial carcinoma).

Program Overview

This enduring webcast will cover topics on the diagnosis, treatment, and management of patients with genitourinary cancers (prostate cancer, renal cell carcinoma and urothelial carcinoma).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Appraise the efficacy and safety of novel combinations of ADT and androgen axis inhibitors in patients with prostate cancer
  • Assess sequential treatment strategies and combination therapies for renal cell carcinoma (RCC) with multitargeted kinase inhibitors
  • Evaluate immunotherapy options with PD-1/PD-L1 checkpoint inhibitors and targeted therapy combinations in the treatment of RCC
  • Outline the immunotherapy and antibody-drug conjugate based therapies for urothelial carcinoma


Nizar M. Tannir, MD

Nizar M. Tannir, MD

Professor and Chair ad interim, Ransom Horne, Jr. Professor in Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, UT MD Anderson Cancer Center, Houston, TX

Robert Motzer, MD

Robert Motzer, MD

Attending Physician, Memorial Sloan-Kettering Cancer Center, Professor of Medicine, Weill Medical College of Cornell University, New York, NY

Amado J Zurita, MD

Amado J Zurita, MD

Associate Professor of Medicine, MD Anderson Cancer Center, Department of Genitourinary Medical Oncology | Division of Cancer Medicine, Houston, TX

Joaquim Bellmunt, MD, PhD

Joaquim Bellmunt, MD, PhD

Director, Bladder Cancer Program, Beth Israel Deaconess Medical Center, Associate Professor of Medicine, Harvard Medical School, Boston, MA

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet, LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

AMA PRA Category 1 Credit(s)
Amedco designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing and Pharmacist Continuing Education
Amedco LLC designates this enduring activity for a maximum of 2.50 contact hours for nurses and 2.50 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity. Event UAN: JA4008163-9999-20-043-L04-P.

Disclosures of Conflicts of Interest

Joaquim Bellmunt, MD, PhD

  • Consultant: Genentech, Merck, Pfizer, GSK, BMS, Pierre-Fabre, Sanofi Aventis, Astellas, OncoGenex, Janssen
  • Speaker: Pfizer, Merck, GSK, Novartis, Pierre-Fabre, Astellas
  • Research Funding: Takeda, Pfizer, Novartis, Sanofi-Aventis

Robert Motzer, MD

  • Consultant: Pfizer, Merck, Genentech Roche
  • Research Funding: BMS, Eisai, Exelixis

Nizar M. Tannir, MD

  • Consultant: Bristol-Myers Squibb, Calithera Bioscience, Eisai Medical Research, Exelixis Inc., Ipsen, Nektar Therapeutics, Novartis, ONO Pharmaceutical, Pfizer Inc., Neoleukin Therapeutics, Merck, Surface Oncology, Lilly
  • Research Funding Bristol-Myers Squibb, Calithera Bioscience, Exelixis Inc., Epizyme, Nektar Therapeutics, Novartis, Mirati Therapeutics, Pfizer Inc., Takeda Pharmaceutical Company Ltd., Arrowhead

Amado J Zurita, MD

  • Consultant: Janssen, Exelixis, Bayer
  • Research Funding:Pfizer, X4 Pharma, Infinity Pharma

Planners and Managers Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

  • Kamatham A. Naidu, PhD (CancerNet, LLC), has no relevant financial relationships.
  • Brian Waggoner (CancerNet, LLC) has no relevant financial relationships to disclose.
  • Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Instructions for Participation and Credit

Generic instructions are part of the site, but you may wish to include specific instructions such as the following. Participation in this activity is free. Understand the material, pass the intra-activity questions and complete an evaluation to receive credit. Passing grade is 70% and you are limited to 5 attempts.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form to the Med Learning Group.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Amedco and CancerNet require that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


Amedco makes every effort to develop CME activities that are scientifically based.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions, please contact: Amedco at:

Contact this CME provider at Amedco for privacy and confidentiality policy statement information at: